IO Biotech (NASDAQ: IOBT) is a clinical‐stage immuno‐oncology company focused on harnessing the body’s immune system to fight cancer. The company’s core mission is to develop novel peptide‐based vaccines and immunotherapies that target immune checkpoints and tumor‐associated antigens. By leveraging proprietary platforms, IO Biotech aims to deliver treatments that elicit robust, durable immune responses against a range of solid tumors.
At the center of IO Biotech’s pipeline is IO102-IO103, a PD-L1 targeting peptide vaccine designed to enhance the efficacy of checkpoint inhibitors in patients with advanced melanoma. This lead candidate is being tested in combination with established PD-1 therapies to improve response rates and extend progression-free survival. In addition to IO102-IO103, the company is advancing next-generation vaccine candidates against colorectal, prostate and other solid tumors, as well as exploring combination strategies with targeted therapies and novel adjuvants.
Founded in 2014 as a spin-out from the University of Copenhagen, IO Biotech is headquartered in Copenhagen, Denmark, with a subsidiary office in New York to support its North American clinical and regulatory efforts. The company’s scientific leadership includes Jacob E. Simonsen as Chief Executive Officer, Charlotte Eide Fredericksen as Chief Medical Officer and Peter Hall as Chief Technical Officer. Their combined expertise spans immunology, clinical development and pharmaceutical manufacturing.
IO Biotech maintains strategic collaborations with academic institutions and contract research organizations across Europe and North America. As it advances its clinical programs, the company continues to expand its manufacturing capabilities and regulatory footprint, positioning itself to address significant unmet needs in oncology through innovative immunotherapeutic solutions.
AI Generated. May Contain Errors.
